Normal tissue dose and risk estimates from whole and partial breast radiation techniques

2019 ◽  
Vol 26 (7) ◽  
pp. 1308-1315
Author(s):  
Sunil W. Dutta ◽  
Eric Aliotta ◽  
Clayton E. Alonso ◽  
Roy C. Bliley ◽  
Kara D. Romano ◽  
...  
Keyword(s):  
Normal Tissue ◽  
Tissue Dose ◽  
Risk Estimates

Normal Tissue Dose Constraints for Multiple Lung Stereotactic Radiotherapy Treatments

2018 ◽  
Vol 30 (7) ◽  
pp. 455 ◽  
Author(s):  
Q. Ghafoor ◽  
B. Allos ◽  
R. Stevenson ◽  
S. Watkins ◽  
S. Yahya ◽  
...  
Keyword(s):  
Stereotactic Radiotherapy ◽  
Normal Tissue ◽  
Tissue Dose ◽  
Dose Constraints

scholarly journals Conversion of computational human phantoms into DICOM-RT for normal tissue dose assessment in radiotherapy patients

2019 ◽  
Vol 64 (13) ◽  
pp. 13NT02 ◽  
Author(s):  
Keith T Griffin ◽  
Matthew M Mille ◽  
Christopher Pelletier ◽  
Mahesh Gopalakrishnan ◽  
Jae Won Jung ◽  
...  
Keyword(s):  
Normal Tissue ◽  
Dose Assessment ◽  
Tissue Dose ◽  
Dicom Rt

scholarly journals Feasibility of normal tissue dose reduction in radiotherapy using low strength magnetic field

2015 ◽  
Vol 33 (3) ◽  
pp. 226 ◽  
Author(s):  
Nuri Hyun Jung ◽  
Youngseob Shin ◽  
In-Hye Jung ◽  
Jungwon Kwak
Keyword(s):  
Magnetic Field ◽  
Dose Reduction ◽  
Normal Tissue ◽  
Tissue Dose ◽  
Low Strength

scholarly journals PO-0928: Normal tissue dose estimation using large databases for automatic plan selection of similar patients

2018 ◽  
Vol 127 ◽  
pp. S500-S501
Author(s):  
W. Van Elmpt ◽  
T. Lustberg ◽  
J. Van Soest ◽  
M. Gooding ◽  
A. Dekker
Keyword(s):  
Normal Tissue ◽  
Dose Estimation ◽  
Tissue Dose ◽  
Large Databases ◽  
Plan Selection ◽  
Selection Of

SU-E-T-678: Normal Tissue Dose-Volume Constrains for Inverse Planning of Acoustic Neuroma Stereotactic Radiosurgery (SRS)

2013 ◽  
Vol 40 (6Part21) ◽  
pp. 362-362
Author(s):  
H Liu ◽  
D Andrews ◽  
M Werner-Wasik ◽  
Y Xiao ◽  
Y Yu ◽  
...  
Keyword(s):  
Stereotactic Radiosurgery ◽  
Acoustic Neuroma ◽  
Normal Tissue ◽  
Inverse Planning ◽  
Tissue Dose ◽  
Dose Volume

Novel Intrauterine Brachytherapy Device Allows Precise Targeting of Tissues at Risk While Simultaneously Minimizing Normal Tissue Dose

Brachytherapy ◽  
2011 ◽  
Vol 10 ◽  
pp. S100-S101
Author(s):  
Daniel J. Scanderbeg ◽  
Cheryl C. Saenz ◽  
Steven C. Plaxe ◽  
Edwin A. Alvarez ◽  
Michael T. McHale ◽  
...  
Keyword(s):  
At Risk ◽  
Normal Tissue ◽  
Tissue Dose

scholarly journals Normal Tissue Dose Constraints for Multiple Lung Stereotactic Radiotherapy Treatments

2020 ◽  
pp. 1-4
Author(s):  
Beshar Allos ◽  
H. Howard ◽  
Beshar Allos ◽  
D. Stange ◽  
J. Bhogal ◽  
...  
Keyword(s):  
Stereotactic Radiotherapy ◽  
Normal Tissue ◽  
Current Evidence ◽  
Normal Lung ◽  
Lung Lesions ◽  
Multiple Lesions ◽  
Tissue Dose ◽  
Dose Constraints

Introduction: The role and use of stereotactic radiotherapy (SABR) is evolving rapidly. A key article by Hanna et al. (2017) provides an excellent overview of current evidence and suggestion of sensible dose constraints. Given the topical nature of this discussion we present a short retrospective analysis of treating multiple lung SABR patients at our centre. Method: We retrospectively analysed toxicity, both early (within 3 months of SABR) and late, and normal tissue dose constraints on all patients who had multiple lung lesions treated with SABR (using volumetric modulated arc therapy (VMAT) technique) at our tertiary centre over a 25-month period from April 2016 until May 2018. Results: We have treated 78 lung lesions in 37 patients with a combination of synchronous lung cancer primaries and lung metastases diagnoses. Median follow-up was 9 months. Almost all patients received treatment on the same day for multiple lesions. We report no grade 3 toxicities in any patient nor any unexpected side effects. 5 patients (14.7%) developed grade 2 pneumonitis. In all 5 patients, lung V12.5 was >20% (range 20.8-32.2%), yet only 1 patient exceeded acceptable lung V20 constraints. Regarding long-term toxicity, 66.6% of patients reported no treatment-related effects. Of 9 patients with long-term toxicity, 8 exceeded V12.5 constraint of <15%, indeed of these 5 were >20%. Lung V20 levels were acceptable for the majority of these. Local control of treated lesions at median follow-up in all comers was 86.2%. Discussion: Our findings show that multiple lung SABR is tolerable, safe with minimal long-term toxicity and acceptable early toxicity. Defining normal lung V12.5 of <15% (optimal) and <20% (acceptable) will significantly reduce the risk of pneumonitis and longer-term toxicity, proving itself more predictive than lung V20 levels for toxicity. Additionally, treating multiple lesions concurrently appears to bare no extra risk to patients.

Sign in / Sign up

Export Citation Format

Share Document